Bioventus (NASDAQ:BVS) Stock Gets Price Target Reduction from Canaccord Genuity Group

Bioventus (NASDAQ:BVS) had its price objective lowered by investment analysts at Canaccord Genuity Group from $19.00 to $18.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price objective points to a potential upside of 36.88% from the company’s current price.

BVS has been the subject of several other reports. Weiss Ratings upgraded shares of Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price target on shares of Bioventus in a research report on Monday, August 17th. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Finally, Barrington Research set a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $16.60.

Bioventus Trading Down 1.3%

Shares of NASDAQ:BVS opened at $13.15 on Tuesday. Bioventus has a 12-month low of $6.47 and a 12-month high of $15.89. The company has a market capitalization of $1.11 billion, a PE ratio of 17.08, a PEG ratio of 1.87 and a beta of 0.64. The business has a 50 day moving average of $13.68 and a two-hundred day moving average of $10.90. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.17 EPS for the quarter, hitting the consensus estimate of $0.17. The business had revenue of $142.44 million for the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%. As a group, analysts forecast that Bioventus will post 0.79 EPS for the current year.

Hedge Funds Weigh In On Bioventus

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Signaturefd LLC lifted its position in Bioventus by 2,809.1% during the third quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock worth $26,000 after buying an additional 1,854 shares in the last quarter. USA Financial Formulas purchased a new stake in Bioventus in the 3rd quarter valued at $42,000. Covestor Ltd grew its holdings in Bioventus by 25.6% in the 3rd quarter. Covestor Ltd now owns 5,808 shares of the company’s stock valued at $79,000 after buying an additional 1,182 shares in the last quarter. Quantum Financial Partners LLC increased its stake in shares of Bioventus by 11.8% in the 3rd quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company’s stock worth $194,000 after acquiring an additional 1,500 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in shares of Bioventus by 446.4% in the 3rd quarter. State of Alaska Department of Revenue now owns 18,953 shares of the company’s stock worth $258,000 after acquiring an additional 15,484 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching analyst expectations and increasing from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS beat or in-line result. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its fiscal 2026 adjusted EPS outlook of $0.75 to $0.79, broadly consistent with the $0.78 consensus estimate. The company’s earnings performance also benefited from debt paydown and lower interest costs. Bioventus Fiscal 2026 Outlook
• Neutral Sentiment: Third-quarter revenue was $142.44 million, while return on equity was 28.08% and net margin was 9.36%. Investors are assessing whether improving profitability can offset slower top-line growth. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut fiscal 2026 revenue guidance to $590 million-$595 million from a level implied by the prior outlook, below the $604.6 million consensus estimate. The reduction signals weaker operational growth and was the main source of investor pressure. Bioventus Sales Miss and Outlook Cut
• Negative Sentiment: Commentary characterized earnings growth as being driven more by debt reduction than by underlying operations, raising concerns about the sustainability of profit improvement if revenue momentum remains limited. Bioventus Earnings Growth and Revenue Outlook

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.